32 PEDs cycle progression

UNIVERSITY

PEDs
Cycle Progression: DHT
Derivatives


Lesson Overview
Cycle Progression after a Testosterone as a Base
Why DHT as a secondary compound?
Proviron Deployment
Masteron Deployment
Primobolan Deployment
Anavar Deployment
Sample Cycle Design


Cycle Progression
Established testosterone is a base growth anchor in our cycle to
support optimal estrogen and DHT levels.
A base testosterone cycle might be cycle 1 and 2, with escalated
dosages
The need for escalating the dosage to continue to grow might be
needed, however continuing to raise testosterone presents issue with
estrogenic side effects.

The next compound to introduce into the cycle would be a DHT
derivative.


Why DHT as a Second Compound

Does not aromatize to estrogen

Increase anabolic activity of cycle, limit androgen activity
Can modulate effect of estrogen and prolactin
Can compete for aromatize and SHBG, making testosterone more
effective
If cycling on and off, DHT derivatives are far less suppressive compared
to nandrolone and trenbolone.
Nandrolone and trenbolone are more advanced in side effect
management so should be saved for when more experienced (can
bind to the AR, ER, and Progestin receptor)


Proviron (Mesterolone)
Clinical Application
1934 first AAS to be marketed
Declining mental capacity, androgen insufficiency, infertility (increasing sperm quality and quantity). Clinical
dosing 25mg TID. 450mg per day for depression.

Properties
Non aromatizing compound, competes with aromatase enzyme, lowers estrogen levels
Competes with SHBG, increase amount of free androgens. 4x higher binding affinity than DHT. Potentiates
other androgens effected by 5 alpha reductase
Not c17aa, low liver toxicity
Dosages >100mg can alter lipid profile (6 months 65.5% increase LDL, and 35.75 HDL decrease)
Highly androgenic, acne and hair loss sensitive individuals be considerate.
Can increase Prolactin (50mg per day)
Does not suppress endocrine testosterone at dosages up 150mg, 300mg can be suppressive
Poor anabolic as 3α -hydroxysteroid dehydrogenase (3α-HSD) breaks it down in skeletal muscle to a weak
androgen

Bodybuilding Application
Offseason:

TRT or blast setting to potentiate free testosterone and offset estrogen (gyno management)
*Caveat higher test dosages can suppress SHBG and saturate aromatase, benefit might be lessened
Libido support, especially in setting of low DHT cycles (great application in nandrolone cycles)
25mg daily can be used throughout year (Much less than clinical dosing, low risk compound)
Contest Prep:
Off set Androgen: Estrogen ratio and decrease Cortisol for “harder” look (lowered water retention)
Libido support
Last 3-4 weeks of Prep dosage can increase from 25mg up to 50mg


Masteron (Drostanolone)
Clinical Application
Introduced for medical use in 1961
Inoperable breast cancer dosage 300mg per week
No longer in clinical usage as Aromatase Inhibitors and SERMS took its place

Properties
Non aromatizing compound, competes with aromatase enzyme, lowers estrogen levels
Typically propionate or enanthate ester for IM injection
Low androgenic profile, designed for androgen sensitive females in mind
Methyl group addition on C2, stabilizes the keto group limiting 3α -hydroxysteroid dehydrogenase
(3α-HSD) activity in skeletal muscle, improving anabolic property compared to DHT
Can modulate prolactin levels

Bodybuilding Application
Offseason:

Increase anabolic profile of stack and modulate estrogen levels
Builds tissue while limiting water retention via no aromatization
Additional Neural drive benefit for strength gains
200-300mg per week as a starting point for a blast phase, can be tapered up in advanced user to
300-500mg per week.
Misconception: “purely cosmetic compound”, this is not the case

Contest Prep:
Utilize as needed in initial phase of prep for estrogen modulation
Deployed or tapered up in dosage in later stages of prep to increase androgen: estrogen ratio for
decreased water retention “hardness”.
Starting at 200mg per week up to 400mg per week.


Primobolan (Methenolone)
Clinical Application
Came to market in 1962
Application in breast cancer, wasting conditions (hemiplegia, stroke), osteoporosis, and anemia
Used in premature infants to promote weight gain
Dosages: 100-200mg per week (highest clinical trial 1200mg/wk compared to 300mg/wk of testosterone in
female breast cancer patients)

Properties
Non aromatizing compound, competes with aromatase enzyme, lowers estrogen levels
Typically enanthate ester for IM injection
Low androgenic profile, designed for androgen sensitive females in mind
Added double bond between carbon 1 and 2, stabilizes the keto group limiting 3α -hydroxysteroid
dehydrogenase (3α-HSD) activity in skeletal muscle, improving anabolic property compared to DHT
Less estrogen modulation effect than masteron, comparative in muscle building capacity *anecdotal note
Highly faked and expensive

Bodybuilding Application
Offseason:
Increase anabolic profile of stack and slight modulation of estrogen
Builds tissue while limiting water retention via no aromatization
300-400mg/wk as a starting point for a blast phase, can be tapered up in advanced user to 400-800mg per
week.
Advanced level: application to cruise on test and primo as bridge into prep
Contest Prep:
Great muscle retention for implementing start of prep, limiting water when body fat is higher, and
aromatization is high
Can be continued to show or swapped to masteron, for great estrogen modulation
Start of prep 300-400mg/wk, higher dosages based on advancement


Anavar (Oxandrolone)
Clinical Application
Ca me to ma rket i n 19060s

FDA a pproved for lean mass preservation i n AIDS wasting, alcoholic hepatitis, turner’s syndrome i n females, delayed
growth a nd puberty i n boys .
Burn pa tients for 2 yea rs post burn
Us ed in premature i nfants to promote weight gain
Dos ages: 2.5-20mg per day for 2-12 weeks
Properties
C17a a oral, mild liver toxi city (12-week HIV study with 20,40,80mg/day; 20mg ha d no l iver elevation, 40mg 30-50%
i ncrease, 80mg 50-100% i ncrease)
CVD: 20mg enough to decrease HDL 30%
Mi l dly s uppressive on endocrine testosterone, 20mg a nd 40mg ca used a 45% reduction.
Two Pha se half l ife: Rapid peak 1 hours post i ngestion, time dosage prior to training a nd s econd dosage later i n day; 300mg
of ca ffeine may enhance bioavailability

Offs et catabolism via glucocorticoid receptor
Non a romatizing compound
Low a ndrogenic profile, designed for a ndrogen sensitive females and children i n mind
Added Oxygen a tom at carbon 2, s tabilizes the keto group l imiting 3α -hydroxys teroid dehydrogenase (3α-HSD) a ctivi ty i n
s keletal muscle, improving anabolic property compared to DHT
Noti ceable strength i ncrease
Bodybuilding Application
Offseason:

Minimal application, limit oral usage to preserve lipid profile
4-6 week minicut may have application to preserve performance, at higher levels of advancement
Contest Prep:
Implemented when needing to preserve training performance. Last 6-8 weeks of contest prep
Dosing: 20-50mg 1-hour pre training w/ 300mg of caffeine


Sample Cycle Progression Offseason
Cycle 1
Test cypionate 250mg/wk
Cycle 2
Test cypionate 350mg/wk
*noted water retention and likely upper level of estrogen
Cycle 3
Test cypionate 350mg/wk
Masteron or Primobolan 300mg/wk
*noticed less estrogenic side effect, titrate up test dosage

Cycle 4
Test cypionate 400mg/wk
Masteron or Primobolan 400mg/wk

Proviron 25mg/day *added for libido and potentiate testosterone


Sample Cycle Progression Contest Prep
Beginner/early intermediate
16 weeks out
Test cypionate 300mg/wk
Primobolan 200mg /wk
10 weeks out
Test cypionate 300mg/wk
Primobolan 200mg/wk
Masteron 200mg/wk *added to modulate estrogen and nitrogen
retention

5 weeks out
Test cypionate 300mg/wk *drop test 2 weeks out if needed for water
retention
Primobolan 200mg/wk
Masteron 200mg/wk
Anavar 30mg/day *add to maintain performance


Summary
Testosterone is our established growth anchor
A DHT derivative like proviron, anavar, primobolan and/or masteron
are secondary compounds to deploy.
We advance up in dosage until we must see out our goals with more
AAS.
By this time we should be experienced in what testosterone and DHT
derivatives do for us regarding growth and sides.

DHT derivates Anadrol and Winstrol will be covered in phase
dependent drug lectures.
Next, we will deploy 19-Nors for more advanced cycle design


References
Proviron:
Itil TM, Michael ST, Shapiro DM, Itil KZ. The effects of mesterolone, a male sex hormone in depressed patients (a double blind controlled study). Methods Find
Exp Clin Pharmacol. 1984 Jun;6(6):331-7. PMID: 6431212.
Saartok T, Dahlberg E, Gustafsson JA. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in
skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology. 1984 Jun;114(6):2100-6. doi: 10.1210/endo-114-6-2100. PMID:
6539197.
Jockenhövel F, Bullmann C, Schubert M, Vogel E, Reinhardt W, Reinwein D, Müller-Wieland D, Krone W. Influence of various modes of androgen substitution
on serum lipids and lipoproteins in hypogonadal men. Metabolism. 1999 May;48(5):590-6. doi: 10.1016/s0026-0495(99)90056-2. PMID: 10337859.

Masteron

Bennett MB, Helman P, Palmer P. Hormonal therapy of breast cancer with special reference toMasteril therapy. S Afr Med J. 1975 Nov 15;49(49):2036-40.
PMID: 1242823.
Dugeroglu H, Ozturk M, Atmaca M, Seven I. Mesterolone treatment of aging male syndrome improves lower urinary tract symptoms. J Pak Med Assoc. 2014
Dec;64(12):1366-9. PMID: 25842579.

Primobolan:

Shimodozono M, Kawahira K, Ogata A, Etoh S, Tanaka N. Addition of an anabolic steroid to strength training promotes muscle strength in the nonparetic
lower limb of poststroke hemiplegia patients. Int J Neurosci. 2010 Sep;120(9):617-24. doi: 10.3109/00207454.2010.505352. PMID: 20707637.
Kennedy BJ, Yarbro JW. Effect of methenolone enanthate (NSC-64967) in advanced cancer of the breast. Cancer. 1968 Feb;21(2):197-201. doi: 10.1002/10970142(196802)21:2<197::aid-cncr2820210207>3.0.co;2-r. PMID: 4952912.

Anavar
Grunfeld C, Kotler DP, Dobs A, Glesby M, Bhasin S. Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebocontrolled study. J Acquir Immune Defic Syndr. 2006 Mar;41(3):304-14. doi: 10.1097/01.qai.0000197546.56131.40. PMID: 16540931.

Reeves PT, Herndon DN, Tanksley JD, Jennings K, Klein GL, Mlcak RP, Clayton RP, Crites NN, Hays JP, Andersen C, Lee JO, Meyer W, Suman OE, Finnerty CC.
FIVE-YEAR OUTCOMES AFTER LONG-TERM OXANDROLONE ADMINISTRATION IN SEVERELY BURNED CHILDREN: A RANDOMIZED CLINICAL TRIAL. Shock. 2016
Apr;45(4):367-74. doi: 10.1097/SHK.0000000000000517. PMID: 26506070; PMCID: PMC4792676.
Strawford A, Barbieri T, Van Loan M, Parks E, Catlin D, Barton N, Neese R, Christiansen M, King J, Hellerstein MK. Resistance exercise and supraphysiologic
androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial. JAMA. 1999 Apr 14;281(14):1282-90. doi:
10.1001/jama.281.14.1282. PMID: 10208143.

Laboratorio de Analises de Dopagem, IDP, Lisboa, Portugal. B. Slema. Oxandrolone excretion: effect of caffeine dowing. Published: www.adop.pt.

Books:

Llewellyn W. Anabolics. Jupiter, FL: Molecular Nutrition LLC; 2017.
Bond P. Book on Steroids: A complete evidence based reference. PeterBond.org; 2020.